Avecho Biotechnology Limited ASX: AVE Share Price & Review

AVE Overview

AVE Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About AVE

Website

Avecho Biotechnology Limited

Telephone

61.3.9002.5000

Address

Unit A8 2A Westall Road Clayton, Victoria (VIC) 3168

Description

Avecho Biotechnology Ltd. engages in the development and commercialization of human and animal products through its proprietary drug delivery system. It operates under the Production and Human Health segments. The Production segment focuses on manufacturing and sale of TPM and Vital ET for the use in drug delivery and cosmetic formulations. The Human Health segment consists of delivery of pharmaceutical products through gels, injectables and patches including conduct of research and development activities. The company was founded by Mark Gregory Kerr on June 19, 1992 and is headquartered in Clayton, Australia.

AVE Price Chart

Key Stats

Market Cap

AU$9.51M

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.01

Trade Value (12mth)

AU$2,843.00

1 week

1 month

50%

YTD

1 year

-50%

All time high

0.42

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

N/A

Operating Cashflow

N/A

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

N/A

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

1931m

HALO Sector

Healthcare

Next Company Report Date

27-Feb-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

AVE Announcements

Latest Announcements

Date	Announcements
13 June 24	Receipt of R&D Tax Incentive × Receipt of R&D Tax Incentive
30 May 24	Chair's Address and CEO Presentation × Chair's Address and CEO Presentation
30 May 24	2024 Annual General Meeting Results × 2024 Annual General Meeting Results
30 May 24	Avecho Biotechnology Limited - Chair's Address and CEO Presentation (AVE-AU) × Avecho Biotechnology Limited - Chair's Address and CEO Presentation (AVE-AU)
30 May 24	Avecho Biotechnology Limited - 2024 Annual General Meeting Results (AVE-AU) × Avecho Biotechnology Limited - 2024 Annual General Meeting Results (AVE-AU)
21 May 24	Notification of cessation of securities - AVE × Notification of cessation of securities - AVE
21 May 24	Avecho Biotechnology Limited - Notification of cessation of securities - AVE (AVE-AU) × Avecho Biotechnology Limited - Notification of cessation of securities - AVE (AVE-AU)
16 May 24	First Patient dosed in Phase III insomnia trial × First Patient dosed in Phase III insomnia trial
30 April 24	March 2024 Quarterly Activities Report & Appendix 4C × March 2024 Quarterly Activities Report & Appendix 4C
30 April 24	Avecho Biotechnology Limited - March 2024 Quarterly Activities Report & Appendix 4C (AVE-AU) × Avecho Biotechnology Limited - March 2024 Quarterly Activities Report & Appendix 4C (AVE-AU)
26 April 24	Appointment of New Director × Appointment of New Director
26 April 24	Notification regarding unquoted securities - AVE × Notification regarding unquoted securities - AVE
26 April 24	Notice of Annual General Meeting/Proxy Form × Notice of Annual General Meeting/Proxy Form
26 April 24	Initial Director's Interest Notice × Initial Director's Interest Notice
26 April 24	Avecho Biotechnology Limited - Appointment of New Director (AVE-AU) × Avecho Biotechnology Limited - Appointment of New Director (AVE-AU)
26 April 24	Avecho Biotechnology Limited - Notification regarding unquoted securities - AVE (AVE-AU) × Avecho Biotechnology Limited - Notification regarding unquoted securities - AVE (AVE-AU)
26 April 24	Avecho Biotechnology Limited - Notice of Annual General Meeting/Proxy Form (AVE-AU) × Avecho Biotechnology Limited - Notice of Annual General Meeting/Proxy Form (AVE-AU)
26 April 24	Avecho Biotechnology Limited - Initial Director's Interest Notice (AVE-AU) × Avecho Biotechnology Limited - Initial Director's Interest Notice (AVE-AU)
22 April 24	Monash Sleep Health Symposium × Monash Sleep Health Symposium
22 April 24	Avecho Biotechnology Limited - Monash Sleep Health Symposium (AVE-AU) × Avecho Biotechnology Limited - Monash Sleep Health Symposium (AVE-AU)
26 March 24	Avecho commences Phase III insomnia trial × Avecho commences Phase III insomnia trial
26 March 24	Avecho Biotechnology Limited - Avecho commences Phase III insomnia trial (AVE-AU) × Avecho Biotechnology Limited - Avecho commences Phase III insomnia trial (AVE-AU)
18 March 24	Avecho to present at NWR Virtual Healthcare Conference × Avecho to present at NWR Virtual Healthcare Conference
18 March 24	Avecho Biotechnology Limited - Avecho to present at NWR Virtual Healthcare Conference (AVE-AU) × Avecho Biotechnology Limited - Avecho to present at NWR Virtual Healthcare Conference (AVE-AU)

Per Share Records

Historical data

Forecast data

	AUD	2021	2022	2023
Per Share, Growth & Valuations
EPS (Basic)	$	-0.00	-0.00	N/A
EPS (Fully Diluted)	$	-0.00	-0.00	N/A
Growth	%	-11.8	31.6	N/A
PE	X	N/A	N/A	N/A
EV/EBITDA	X	N/A	N/A	N/A
CFPS	$	-0.00	-0.00	N/A
FCFPS	$	-0.00	N/A	N/A
Growth	%	-19.9	30.9	N/A
Yield	%	-12.2	N/A	N/A
DPS	$	0.00	N/A	N/A
Growth	%	N/A	N/A	N/A
Yield	%	N/A	N/A	N/A
Payout Ratio	%	0	N/A	N/A
BPS	$	0.00	0.00	N/A
BPS (Tangible)	$	0.00	0.00	N/A
Growth	%	73.7	-46.0	N/A
Shares Outstanding
Diluted	m	1,802	N/A	N/A
Basic	m	1,802	N/A	N/A

Financial Records

Historical data

Forecast data

	AUD	2021	2022	2023
Income Statement
Sales	$m	1	1	N/A
Growth	%	106.3	42.3	N/A
Selling & General Expenses	$m	4	4	N/A
Gross Income	$m	-1	1	N/A
Growth	%	53.9	200.2	N/A
Margin	%	-99.8	70.2	N/A
Cost of Goods Sold to Sales	%	200	30	N/A
EBITDA	$m	-4	N/A	N/A
Growth	%	-44.6	N/A	N/A
Margin	%	-519.4	N/A	N/A
Depreciation & Amortisation	$m	0	N/A	N/A
EBIT	$m	-5	-3	N/A
Growth	%	-34.3	32.7	N/A
Margin	%	-573.4	-271.3	N/A
Pretax Income	$m	-5	-3	N/A
Income Taxes	$m	-1	-1	N/A
Net Income	$m	-3	-2	N/A
Growth	%	-29.7	31.4	N/A
Margin	%	-430.5	-207.4	N/A
Cash Flow Statement
Net Operating Cash Flow	$m	-3	-2	N/A
Capital Expenditures	$m	0	0	N/A
Net Investing Cash Flow	$m	0	0	N/A
Net Financing Cash Flow	$m	5	0	N/A
Free Cash Flow	$m	-3	-2	N/A
Growth	%	-131.1	48.0	N/A
Margin	%	-4.2	-1.5	N/A
Franking Balance	$m	N/A	N/A	N/A
Balance Sheet
Cash & Short-Term Investments	$m	3	1	N/A
Total Assets	$m	5	3	N/A
Long Term Debt	$m	0	0	N/A
Net Debt	$m	-3	-1	N/A
Total Liabilities	$m	1	1	N/A
Equity	$m	5	2	N/A
Invested Capital		5	3	N/A
Growth	%	65.6	-42.9	N/A
Return Ratios
Return on Assets	%	-65.1	-70.0	N/A
Return on Equity	%	-75.3	-96.6	N/A
Return on Total Capital	%	-122.1	-83.9	N/A
Return on Invested Capital	%	-93.6	-65.5	N/A
Cash Flow Return on Invested Capital	%	-84.9	-46.6	N/A

Ratios Records

Historical data

Forecast data

	AUD	2021	2022	2023
Leverage
Interest Cover	X	-413.2	N/A	N/A
Debt to EBITDA	X	0.8	N/A	N/A
Net Debt to Equity	%	-69.9	-50.4	N/A
Liquidity
Current Ratio	X	6.9	3.8	N/A
Quick Ratio	X	6.6	3.3	N/A
Cash & ST Inv/Current Assets	%	67.9	51.5	N/A
CFO/Current Liabilities	%	-445.4	-223.4	N/A
Balance Sheet Efficiency
Receivables Turnover	X	1.0	1.2	N/A
Inventory Turnover	X	10.7	1.1	N/A
Working Capital Turnover	X	0.2	0.5	N/A
Payables Turnover	X	9.5	16.9	N/A
Asset Turnover	X	0.2	0.3	N/A
Du Pont
Asset Turnover	X	0.2	0.3	N/A
x Pretax Margin	%	-572.2	-262.6	N/A
= Pretax Return on Assets	%	-86.6	-88.6	N/A
x Tax Rate Complement (1-Tax Rate)	%	N/A	N/A	N/A
Return on Assets	%	-65.1	-70.0	N/A
x Equity Multiplier (Assets/Equity)	%	1.2	1.4	N/A
Return on Equity	%	-75.3	-96.6	N/A
x Earnings Retention (1-Payout)	%	100.0	N/A	N/A
= Reinvestment Rate (%)	%	-75.3	N/A	N/A
Operating Cycle
Days of Inventory on Hand	Days	34.2	325.1	N/A
+ Days of Sales Outstanding	Days	369.3	302.7	N/A
Operating Cycle	Days	403.5	627.7	N/A
- Days of Payables Outstanding	Days	20.1	89.8	N/A
Net Operating Cycle	Days	383.4	538.0	N/A

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Falling Divs over next 2

Values and Recommendations

Key Stats

Consensus Score

Recommendation

EPS 1 month Change

Quality Yield

Falling Divs over next 2

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

AVE Shortsell

Frequently Asked Questions

What is the current share price of Avecho Biotechnology Limited (AVE:ASX)?

The current share price of Avecho Biotechnology Limited (AVE:ASX) is AU$0.003.

What is the 52-week high share price for Avecho Biotechnology Limited (AVE:ASX)?

The 52-week high share price for Avecho Biotechnology Limited (AVE:ASX) is AU$0.01.

What is the 52-week low share price for Avecho Biotechnology Limited (AVE:ASX)?

The 52-week low share price for Avecho Biotechnology Limited (AVE:ASX)? is AU$0.00.

What is the dividend yield for Avecho Biotechnology Limited (AVE:ASX)?

Avecho Biotechnology Limited (AVE:ASX) does not pay a dividend.

What was Avecho Biotechnology Limited (AVE:ASX) last dividend payment?

Avecho Biotechnology Limited (AVE:ASX) does not pay a dividend.

What is the franking level for Avecho Biotechnology Limited (AVE:ASX)?

Avecho Biotechnology Limited (AVE:ASX) has a franking level of 0.0%.

In which sector is Avecho Biotechnology Limited (AVE:ASX) classified?

Avecho Biotechnology Limited (AVE:ASX) is classified in the Healthcare.

The current P/E ratio for Avecho Biotechnology Limited (AVE:ASX) is .

Company

Important

Get the latest insights and hot tips delivered right to your inbox

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.

AVE · ASX

Avecho Biotechnology Limited (ASX:AVE)

AU$0.003

AVE Overview

AVE Health Scores

About AVE

AVE Price Chart

Key Stats

AU$9.51M

N/A

N/A

Dividends Overview

N/A

N/A

N/A

Market Data

Key Fundamentals

Other Data

AVE Announcements

Latest Announcements

Receipt of R&D Tax Incentive

Chair's Address and CEO Presentation

2024 Annual General Meeting Results

Avecho Biotechnology Limited - Chair's Address and CEO Presentation (AVE-AU)

Avecho Biotechnology Limited - 2024 Annual General Meeting Results (AVE-AU)

Notification of cessation of securities - AVE

Avecho Biotechnology Limited - Notification of cessation of securities - AVE (AVE-AU)

First Patient dosed in Phase III insomnia trial

March 2024 Quarterly Activities Report & Appendix 4C

Avecho Biotechnology Limited - March 2024 Quarterly Activities Report & Appendix 4C (AVE-AU)

Appointment of New Director

Notification regarding unquoted securities - AVE

Notice of Annual General Meeting/Proxy Form

Initial Director's Interest Notice

Avecho Biotechnology Limited - Appointment of New Director (AVE-AU)

Avecho Biotechnology Limited - Notification regarding unquoted securities - AVE (AVE-AU)

Avecho Biotechnology Limited - Notice of Annual General Meeting/Proxy Form (AVE-AU)

Avecho Biotechnology Limited - Initial Director's Interest Notice (AVE-AU)

Monash Sleep Health Symposium

Avecho Biotechnology Limited - Monash Sleep Health Symposium (AVE-AU)

Avecho commences Phase III insomnia trial

Avecho Biotechnology Limited - Avecho commences Phase III insomnia trial (AVE-AU)

Avecho to present at NWR Virtual Healthcare Conference

Avecho Biotechnology Limited - Avecho to present at NWR Virtual Healthcare Conference (AVE-AU)

AVE Fundamentals

Per Share Records

Financial Records

Ratios Records

Dividends

Key Stats

N/A

N/A

N/A

N/A

Values and Recommendations

Key Stats

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

0.00%

0

N/A

N/A

N/A

N/A

Discover Short-sellingOpportunities

AVE Shortsell

Related Companies

Frequently Asked Questions

Company

Company

Important

Discover
Short-selling
Opportunities